B-depleting therapies increase the risk of severe COVID-19 [1] and have been shown to induce an impaired immune response to the SARS-COV2 vaccine [2]. There is a lack of data exploring the T-cell response to SARS COV2 vaccine [3,4], especially since it may be preserved in patients treated with rituximab [5].
